Influence of dapagliflozin on cardiovascular remodeling in hypertensive patients with accompanying type 2 diabetes

Influence of dapagliflozin on cardiovascular remodeling in hypertensive patients with accompanying type 2 diabetes

Aim. To compare the results of 12-week treatment of patients with stage II hypertension (HTN) with accompanying diabetes mellitus (DM) type 2 between the combination of metformin + dapagliflozin and metformin monotherapy by studying changes in the elastic properties of the common carotid arteries (C...

Full description

Saved in:

Bibliographic Details
Main Author:	A. O. Bohun
Format:	Article
Language:	English
Published:	Zaporizhzhia State Medical and Pharmaceutical University 2024-04-01
Series:	Patologìâ
Subjects:	dapagliflozin sglt2 inhibitors vascular stiffness hypertension type 2 diabetes
Online Access:	http://pat.zsmu.edu.ua/article/view/299196/294563
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
by: Olga Yuryevna Sukhareva, et al.
Published: (2016-01-01)

Impact of dapagliflozin on life expectancy in type 2 diabetes mellitus patients in routine practice
by: M. B. Antsiferov, et al.
Published: (2023-08-01)

DRESS syndrome with the use of dapagliflozin: A case report and review of literature
by: Rebecca Badawi, et al.
Published: (2025-07-01)

Assessing the Efficacy and Safety of Dapagliflozin and Empagliflozin as an Add-on Therapy for Lowering Glycated Hemoglobin and Weight in Type 2 Diabetes Mellitus Patients
by: Mahima Makhija, Alka Bansal, Lokendra Sharma, Punam Jakhar, Susheel Kumar, Ashish Agrawal
Published: (2025-06-01)

Effect of dapagliflozin on the structural and functional properties of arterial vessels in patients with type 2 diabetes mellitus in combination with obesity
by: О. А. Soloviuk, et al.
Published: (2020-12-01)

COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN
by: V. I. Petrov, et al.
Published: (2016-04-01)

INFLUENCE OF TYPE 2 SODIUM-GLUCOSE CO-TRANSPORTER INHIBITORS (DAPAGLIFLOZIN) ON THE INDICATORS OF TOTAL MORTALITY IN PATIENTS WITH TYPE 2 DIABETES (CARDIA-MOS STUDY, MOSCOW)
by: Mikhail B. Antsiferov, et al.
Published: (2022-12-01)

Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study
by: Zinan Zhao, et al.
Published: (2025-04-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
by: Yan Tian, et al.
Published: (2025-12-01)

Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow)
by: M. B. Antsiferov, et al.
Published: (2022-12-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
by: Arif Albulushi, et al.
Published: (2025-07-01)

Vascular Remodeling Markers in Patients with Essential Arterial Hypertension Depending on Presence of Type 2 Diabetes Mellitus
by: Yu. A. Danilogorskaya, et al.
Published: (2019-07-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Discrepancies in Dapagliflozin Response in Terms of Glycemic Control and Body Weight Reduction
by: Ji Eun Jun, et al.
Published: (2025-04-01)

Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA‐SRV Trial
by: Mathieu Albertini, et al.
Published: (2025-06-01)

Dapagliflozin effectiveness in improvement of clinical outcomes in diabetic patients (extention of CARDIA-MOS study, Moscow)
by: M. B. Antsiferov, et al.
Published: (2025-02-01)

Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Calcium Homeostasis: Where We Stand Now
by: Alessandro Cuttone, et al.
Published: (2025-05-01)

Mottling as an early sign of euglycemic ketoacidosis induced by SGLT-2 inhibitors
by: Besard Memeti, et al.
Published: (2025-03-01)

Enhancing Diabetes Treatment: Comparing Pioglitazone/Metformin with Dapagliflozin Versus Basal Insulin/Metformin in Type 2 Diabetes
by: Lin Y, et al.
Published: (2025-03-01)

Effectiveness of Dapagliflozin in Treating Type 2 Diabetes Mellitus in a Real-World Indian Setting
by: Uday M. Jadhav, et al.
Published: (2025-04-01)

Empagliflozin Leads to Faster Improvement in Arterial Stiffness Compared to Dapagliflozin: A Double-Blind Clinical
by: Erick González Campos, et al.
Published: (2025-05-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China
by: Huiyuan Zhang, et al.
Published: (2025-07-01)

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial
by: Mohammad Abdel Jawad, et al.
Published: (2025-07-01)

Efficacy and prognosis of dapagliflozin in the treatment of patients with acute myocardial infarction complicated with type 2 diabetes in Xining area
by: Jinping Chai, et al.
Published: (2025-02-01)

SGLT2 Inhibitors and genital infections: a prospective observational study in a tertiary care hospital
by: Numan Malik, et al.
Published: (2025-07-01)

Sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reverses depressive-like behavior in a mouse model of post-traumatic stress disorder
by: Haneen Amawi, et al.
Published: (2025-08-01)

Corrigendum: Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2025-02-01)

Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?
by: Massimo Mapelli, et al.
Published: (2025-03-01)

Efficacy and Safety of Pioglitazone Add‐On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
by: Ubaid Khan, et al.
Published: (2025-05-01)

The influence of carotid plaque on carotid artery stiffness indicators in hypertensive patients with and without accompanying type 2 diabetes
by: V. V. Syvolap, et al.
Published: (2024-02-01)

Dapagliflozin combined with methylcobalamin in the treatment of type 2 diabetes mellitus with peripheral neuropathy: a systematic review and meta-analysis
by: Xiao-Long Deng, et al.
Published: (2025-06-01)

The Effects of SGLT2 Inhibitors on Lipid Profile and Kidney Function in Patients with Chronic Kidney Disease Regardless of Diabetes and Hypertension Status
by: Selena Gajić, et al.
Published: (2025-04-01)

Dapagliflozin improves cardiac function and reduces adverse events in myocardial infarction: a meta-analysis in diabetic and non-diabetic populations
by: Shuang Li, et al.
Published: (2025-06-01)

Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness
by: Adarsh Raja, et al.
Published: (2024-12-01)

Impact of dapagliflozin administration on remodeling marker and clinical outcomes of stemi patients with diabetes mellitus: a controlled clinical trial
by: Abdullah Heshmat, et al.
Published: (2025-08-01)

Dapagliflozin prevents vascular ischemia-reperfusion injury in healthy young males: a randomized, placebo-controlled, double-blinded trial
by: Martin Lutnik, et al.
Published: (2025-05-01)

State of a large vessels and microcirculation - a new target for antihypertensive therapy in patients with hypertension and type 2 diabetes
by: M. E. Statsenko, et al.
Published: (2017-01-01)